Abstract
England has experienced a heavy burden of COVID-19, with high infection levels observed throughout the summer months of 2021. Alongside the emergence of evidence suggesting that COVID-19 vaccine protection wanes over time, booster vaccinations began for individuals aged 50 and above in September 2021. Using a model fitted to 18 months of epidemiological data, we project potential dynamics of SARS-CoV-2 transmission in England to September 2022. We consider key uncertainties including behavioural change, waning vaccine protection, strategies for vaccination, and the reintroduction of public health and social measures. We project the current wave of transmission will peak in Autumn 2021, with low levels of transmission in early 2022. The extent to which SARS-CoV-2 transmission resurges in 2022 depends largely on assumptions around waning vaccine protection and booster vaccinations. Widespread booster vaccinations or the reimposition of mild public health and social measures such as work-from-home policies could largely mitigate the wave of COVID-19 transmission projected to occur in England in Spring/Summer 2022.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The following funding sources are acknowledged as providing funding for the named authors. This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688: RCB, MJ, WJE) and the UK Medical Research Council (MC_PC_19065: NGD, WJE). It was also partly funded by the Bill & Melinda Gates Foundation (INV-003174 and INV-016832: MJ) and the National Institute for Health Research (NIHR) (Health Protection Research Unit for Immunisation NIHR200929: NGD, MJ; Health Protection Research Unit in Modelling and Health Economics NIHR200908: MJ, WJE; PR-OD-1017-20002: WJE).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this research was given by the London School of Hygiene & Tropical Medicine Ethics Committee, project ID: 22828.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† See end material for working group authors
Data Availability
Analysis code and data will be made available upon publication at: https://github.com/rosannaclairebarnard/newcovid3
